The yeast CNCM I-745 is one of the probiotics recommended for the prevention of antibiotic-associated diarrhea. Studies conducted and demonstrated that in the case of infectious diseases there are two potential sites of action of CNCM I-745: (1) An action on enteropathogenic microorganisms (adhesion of bacteria and their elimination or an effect on their virulence factors: Toxins, lipopolysaccharide, .); and (2) a direct action on the intestinal mucosa (trophic effects, effects on epithelial reconstitution, anti-secretory effects, anti-inflammatory, immunomodulators). Oral administration of CNCM I-745 to healthy subjects does not alter their microbiota. However, in the case of diseases associated with the use of antibiotics or chronic diarrhea, CNCM I-745 can restore the intestinal microbiota faster. The interaction of CNCM I-745 with the innate immune system have been recently demonstrated thus opening up a new therapeutic potential of this yeast in the case of diseases associated with intestinal infections but also other pathologies associated with dysbiosis such as inflammatory diseases.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526157PMC
http://dx.doi.org/10.3748/wjg.v25.i18.2188DOI Listing

Publication Analysis

Top Keywords

cncm i-745
24
action intestinal
8
intestinal infections
8
case diseases
8
diseases associated
8
i-745
6
cncm
5
diversity cncm
4
i-745 mechanisms
4
action
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!